Clinical Translation of Deformation Compensation for Image-Guided Liver Surgery

描述（由申请人提供）：在某种程度上，主流科学界尚未接受使用软组织建模来更新图像引导导航系统。它只是最近才在神经导航社区中找到应用（尽管还没有商业系统可用），并且仍在调查中。这种挫折感在很大程度上不是由于方法数量的增加，而是由于对模型更新目标的误解，以及无法进行测试和验证。关于前者，我们还不太相信模型可以解释所有的精细变形。然而，需要回答的问题是，在手术切缘的范围内，模型更新是否会显著影响手术切除？这是本申请中要研究的中心研究假设。使该应用与众不同的是，如果实现了里程碑，结果可能导致用于图像引导肝脏手术系统的软组织变形校正系统，其可以立即商业化用于患者护理。更具体地说，在这项工作结束时，将生成能够进行变形校正的图像引导肝脏手术系统，将建立这些校正的保真度的初步经验，并且该技术将在商业上可用。这是可能的，因为该应用程序将利用与Pathfinder Therapeutics Incorporated（PTI）的持续关系，该公司正在测试其图像引导肝脏手术（IGLS）系统和Memorial Sloan Kettering Cancer Center的独立临床评估员。PTI已同意与PD共享其技术平台，并提供开放系统和支持，以支持本文提出的新型组织变形校正策略的整合。PTI团队的成员已经为本申请中的方法学做出了贡献，并具有在本申请范围内继续使用PD的既定科学兴趣。模型可用于校正IGLS内的变形的假设将得到三个具体目标的支持，这三个具体目标涉及：（1）将非刚性校正计算节点控制器并入Pathfinder Therapeutics Inc.引导平台，测试，然后部署到我们的临床研究中心，（2）在临床试验中使用计算节点控制器评估术中变形校正，以及（3）开始在微创手术的背景下研究控制器/系统。以前的工作涉及我们的注册方法和变形校正计算节点控制器的发展。我们在这一奋进中取得了成功，并表现出了希望。我们准备完成下一阶段，部署到市售的IGLS系统中，并在两项25名患者的研究中在独立的临床研究中心进行测试，以及解决微创手术。此外，应该注意的是，虽然控制器将被集成到特定的平台中，但该技术本身可以与任何图像引导手术平台集成。

DESCRIPTION (provided by applicant): To a degree, the use of soft-tissue modeling for updating image-guided navigational systems has not been embraced by the mainstream scientific community. It has only just recently found application within the neuronavigation community (although no commercial systems are available yet) and is still under investigation. Much of this frustration is not due to the growing number of methodologies but rather to a misunderstanding of the goals of model-updating, and an inability to test and validate. With respect to the former, it is naove to believe that modeling can account for all fine-scale deformations. However, the question to be answered is, within the confines of surgical margin, can model-updating significantly impact surgical resection? This is a central research hypothesis to be investigated within this application. What sets this application apart is that if the milestones are achieved, the outcome could result in a soft-tissue deformation correction system for image- guided liver surgery systems that could be immediately commercially available for patient care. More specifically, at the conclusion of this work, an image-guided liver surgical system capable of deformation correction will be generated, a preliminary experience with the fidelity of those corrections will be established, and the technology will be commercially available. This is possible because this application will leverage an ongoing relationship with Pathfinder Therapeutics Incorporated (PTI) that is in the process of testing their image-guided liver surgery (IGLS) system and an independent clinical evaluator at Memorial Sloan Kettering Cancer Center. PTI has agreed to share their technological platform with the PD as well as provide open systems and support to support the integration of the novel tissue deformation correction strategy proposed herein. Members of the PTI team have already contributed to the methodologies within this application and have vested scientific interest to continue within the scope of this application with the PD. The hypothesis that models can be used to correct for deformation within IGLS will be supported by three specific aims which involve: (1) incorporate the non-rigid correction compute node controller into the Pathfinder Therapeutics Inc. guidance platform, test, and then deploy to our clinical site, (2) evaluate intraoperative deformation correction using the compute node controller in a clinical trial, and (3) begin to investigate the controller/system within the context of minimally invasive procedures. Previous work involved the development of our registration methods and deformation correction compute node controller. We have succeeded in this endeavor and have shown promise. We are poised to complete the next phase with the deployment into a commercially available IGLS system, and the testing at an independent clinical site in two 25 patient studies as well as address minimally invasive procedures. In addition, it should be noted that while the controller will be integrated into a specific platform, the technology itself is amenable to integration with any image-guided surgery platform.